Protein Discovery Could Help Tackle Breast Cancer Resistance
Researchers identified a protein that helps cancer cells resist chemotherapy, potentially aiding future treatment options.
Updated on Oct. 21, 2026 in Cancer
Live Poll
Do you trust that recent scientific discoveries in cancer research will soon improve your treatment options?
Researchers at Roswell Park Comprehensive Cancer Center have identified that the protein MPP8 drives chemotherapy resistance in triple-negative breast cancer. This discovery may eventually help clinicians better tailor treatment plans for patients facing this aggressive cancer type.
Why it matters
About half of all triple-negative breast cancer patients experience tumors that do not respond to chemotherapy. This research identifies a specific protein that helps cancer cells repair DNA damage, potentially offering a new target for improving treatment outcomes.
A preclinical study published in the journal Advanced Science identified that the protein MPP8 promotes DNA repair in human cancer cells. While the finding clarifies how 50% of triple-negative breast cancer patients develop resistance, it remains preliminary as clinical trials are pending.
The players
Roswell Park Comprehensive Cancer Center
A Buffalo-based cancer research institution that focuses on the study and treatment of complex malignancies.
Dr. Jia Fang
A researcher known for studying the role of protein signaling and genetic pathways in cancer metastasis.
National Cancer Institute
The federal government's primary agency for cancer research and training that provides funding for scientific studies.
The details
MPP8 resides in the nucleus and plays a role in how cells manage DNA processes. In breast cancer cells, high levels of MPP8 allow tumors to utilize the dominant DNA double-strand break repair pathway, which fixes the cellular damage typically inflicted by chemotherapy. By suppressing MPP8 expression, researchers demonstrated that they could make these cancer cells vulnerable to treatment again.
Timeline
2010: Dr. Jia Fang published early findings on how MPP8 silences tumor-suppressing genes.
October 21, 2026: Research findings were published in the journal Advanced Science.
Health Landscape
This finding builds on a long history of cancer research aimed at overcoming treatment resistance in aggressive tumors like triple-negative breast cancer. It contributes to the expanding effort to characterize specific protein signatures that could eventually inform personalized medicine approaches.
If you are currently undergoing treatment for triple-negative breast cancer, these findings represent an early-stage discovery rather than an immediate change to clinical practice. Discuss your tumor’s specific biology and your treatment path with your oncologist to understand your unique care plan.
The takeaway
The discovery of the MPP8 protein helps explain why some breast cancers resist standard chemotherapy. Patients should continue to work closely with their oncology team to monitor treatment response and discuss emerging research relevant to their specific tumor profile.
Further reading
For more on the current approach to managing complex malignancies, see the Cancer section.
Source note: This article includes information reported by Buffalo News.
Live Poll
Do you trust that recent scientific discoveries in cancer research will soon improve your treatment options?
